ACTU ACTUATE THERAPEUTICS, INC.

Nasdaq actuatetherapeutics.com


$ 6.00 $ 0.11 (1.87 %)    

Tuesday, 18-Nov-2025 14:25:08 EST
QQQ $ 599.47 $ -0.05 (-0.03 %)
DIA $ 462.82 $ 0.66 (0.14 %)
SPY $ 663.07 $ 0.94 (0.14 %)
TLT $ 89.02 $ -0.33 (-0.37 %)
GLD $ 375.03 $ 0.19 (0.05 %)
$ 5.92
$ 5.89
$ 5.88 x 8
$ 6.10 x 100
$ 5.90 - $ 6.00
$ 5.47 - $ 11.99
64,809
na
137.6M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 09-24-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...

Core News & Articles

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current ...

Core News & Articles

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Core News & Articles

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Core News & Articles

-SEC Filing

Core News & Articles

B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and an...

Core News & Articles

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

Core News & Articles

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT ...

Core News & Articles

 On June 25, 2025, Actuate Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Se...

Core News & Articles

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in ris...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION